GENE EXPRESSION PROFILING IDENTIFIES CHARACTERISTIC TRANSCRIPTIONAL SIGNATURES OF GENOMIC INSTABILITY IRRESPECTIVE OF TP53 IMPAIRMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Johannes Bloehdorn, 214639
ROLE OF MTORC1 IN NORMAL HAEMOPOIESIS AND LEUKAEMOGENESIS
EHA Learning Center, Natasha Malik, 214655
CLONAL EVOLUTION OF ACUTE LYMPHOBLASTIC LEUKEMIA CELLS FROM DIAGNOSIS TO RELAPSE
EHA Learning Center, shumaila sayyab, 215239
PROTEOLYTIC L-ASPARAGINASE DEGRADATION AS A MECHANISM FOR NON-ANTIBODY-RELATED DRUG INACTIVATION
EHA Learning Center, Justyna Walenciak, 215256
SYNERGISTIC INHIBITORY EFFECT OF HYDROXYUREA AND DECITABINE ON THE PROLIFERATION OF AML CELLS
EHA Learning Center, Konstantin Byrgazov, 215273
IDENTIFICATION OF GENE COPY NUMBER ABERRATIONS AS PROGNOSTIC MARKERS OF SURVIVAL IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS BY EXOME SEQUENCING OF LEUKEMIA DNA IN THE MAYO CLINIC AML EPIDEMIOLOGY COHORT
EHA Learning Center, Yan Asmann, 215290
PH II TRIAL WITH SELECTIVE ORAL AXL INHIBITOR BEMCENTINIB (BGB324) IN RELAPSED/REFRACTORY AML AND MDS: IDENTIFICATION OF PREDICTIVE AND PHARMACODYNAMIC BIOMARKER CANDIDATES ASSOCIATED WITH PT BENEFIT
EHA Learning Center, Julia Schoelermann, 215306
ANALYSIS OF PHASE I AND PILOT PHASE II DATA REVEAL 2,000 MG/M2 AS THE OPTIMAL DOSE OF CPI-613 IN COMBINATION WITH CYTARABINE AND MITOXANTRONE FOR ELDERLY PATIENTS WITH RELAPSED OR REFRACTORY AML
EHA Learning Center, Timothy Pardee, 215322
EXTRACELLULAR CIRCULATING DNA IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: BIOLOGICAL CORRELATES AND PROGNOSTIC IMPACT
EHA Learning Center, Dino Dujmovic, 215338
GLOBAL LONGITUDINAL STRAIN (2D-GLS) IN LYMPHOMA PATIENTS TREATED WITH CHEMOTHERAPY +/- MEDIASTINAL RADIOTHERAPY: EARLY SUBCLINICAL CARDIOTOXICITY IN THE CARDIOCARE PROSPECTIVE OBSERVATIONAL STUDY.
EHA Learning Center, Barbara Botto, 215353
CLINICAL FEATURES, TREATMENT AND PROGNOSTIC FACTORS FOR EXTRANODAL NATURAL KILLER/T-CELL LYMPHOMA, NASAL TYPE, IN THE SPANISH POPULATION. A STUDY FROM THE SPANISH GROUP GELTAMO.
EHA Learning Center, EVA GONZALEZ BARCA, 215354
CONGENITAL FXIII DEFICIENCY IN PAKISTAN
EHA Learning Center, Munira Borhany, 215369
DISSEMINATED INTRAVASCULAR COAGULATION SCORING IN CHILDREN WITH ACUTE LEUKEMIA: IS THERE A SIMPLER AND ECONOMICAL ALTERNATIVE?
EHA Learning Center, Yasmine El Chazli, 215370
HIGHER RATE OF DYSMORPHIC FEATURES IN PATIENTS WITH DIAMOND BLACKFAN ANEMIA
EHA Learning Center, Sule Unal, 215385
OPTIMIZING MRD RESPONSE ASSESSMENT USING HIGH-SENSITIVITY PERIPHERAL BLOOD MONITORING DURING TREATMENT WITH IBRUTINIB COMBINED WITH OBINUTUZUMAB OR VENETOCLAX IN CLL .
EHA Learning Center, Andy C. Rawstron, 215386
SINGLE CELL ABNORMALITIES ON CLASSIC G-BANDING ANALYSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA: A NEW DIAGNOSTIC AND BIOLOGICAL CHALLENGE?
EHA Learning Center, Anastasia Athanasiadou, 215402
HIGHER RESPONSIVENESS OF CLL CELLS TO B-CELL RECEPTOR STIMULATION IS ASSOCIATED WITH REDUCED EXPRESSION OF INHIBITORY MOLECULES OF THE NF-ΚB PATHWAY
EHA Learning Center, Ruud Meijers, 215403
HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN RELATION TO RESPONSE TO FIRSTLINE THERAPY AND SUBSEQUENT TREATMENTS – A METAANALYSIS OF HRQOL MEASURED IN PHASE III TRIALS OF THE GERMAN CLL STUDY GROUP
EHA Learning Center, Nadine Kutsch, 215418
T-LARGE GRANULAR LYMPHOCYTIC (T-LGL) LEUKEMIA: A LONG-TERM STUDY ON 51 PATIENTS-COULD WE CONFINE THE USE OF THE TERM “LEUKEMIA”?
EHA Learning Center, Xanthi Yiakoumis, 215419
TWO YEARS OF THERAPY WITH MATINIB GENERICS IN CHRONIC MYELOID LEUKEMIA; A REPORT FROM THE POLISH ADULT LEUKEMIA GROUP (PALG) IMATINIB GENERICS REGISTRY
EHA Learning Center, Tomasz , 215434
MAINTENANCE THERAPY WITH DASATINIB ADMINISTRATED EVERY OTHER DAY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
EHA Learning Center, Clemence Loiseau, 215435
PREVALENCE AND CLINICAL SIGNIFICANCE OF SMALL PNH CLONES IN PATIENTS WITH PRIMARY AUTOIMMUNE HEMOLYTIC ANEMIA
EHA Learning Center, Bruno Fattizzo, 215451
COMBINATION TREATMENT OF RITUXIMAB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE FOR WARM AUTOIMMUNE HEMOLYTIC ANEMIA
EHA Learning Center, Caroline Piatek, 215452
INITIAL EXPERIENCE IN US COMMERCIAL MANUFACTURING OF TISAGENLECLEUCEL, A CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL THERAPY FOR PEDIATRIC RELAPSED/REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Brian Majors, 215467
ALLOGENEIC NK CELLS AND THEIR USE IN CLINICAL TRIALS
EHA Learning Center, Ludovit Bielik, 215468
NIVOLUMAB RESTORES SENSITIVITY TO CHEMOTHERAPY IN CHEMOREFRACTORY CLASSICAL HODGKIN LYMPHOMA PATIENTS
EHA Learning Center, Carmelo Carlo-Stella, 215484
CD5-NEGATIVE MANTLE CELL LYMPHOMA: A DIAGNOSTIC CHALLENGE IN LEUKEMIC NON-NODAL CASES EXCLUSIVELY DIAGNOSED IN PERIPHERAL BLOOD
EHA Learning Center, Sara Montesdeoca Romero, 215500
CHARACTERISTICS OF HEMATOLOGICAL PATIENTS WITH BLOOD CULTURES PROVEN SEPSIS – EXPERIENCE OF ONE CENTER
EHA Learning Center, Karla Jakobac, 215518
GROWING IMPORTANCE OF FLOW CYTOMETRY (FCM) IN THE DIAGNOSTICS OF MYELODYSPLASTIC SYNDROMES: SENSITIVITY AND SPECIFICITY OF THE UP-TO-DATE SCORING SYSTEMS UNDER SPECIAL CONSIDERATION OF THE NEW IFSCORE
EHA Learning Center, Uta OELSCHLAEGEL, 215534
HYPOMETHYLATING AGENTS ASSOCIATED INFECTIONS - SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
EHA Learning Center, Liat shargian-alon, 215550
SYSTEMATIC IDENTIFICATION OF PHARMACOGENOMICS INTERACTIONS MODULATING DRUG RESPONSES IN MULTIPLE MYELOMA
EHA Learning Center, Muntasir Majumder, 215567
TARGETED LIPOSOMAL MULTI-DRUG DELIVERY TO TUMOR-ASSOCIATED ENDOTHELIUM AS A NOVEL STRATEGY TO REVERSE MICROENVIRONMENT-INDUCED DRUG RESISTANCE IN MULTIPLE MYELOMA
EHA Learning Center, Cinzia Federico, 215583
LENALIDOMIDE-PREDNISONE VS LENALIDOMIDE ALONE MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: INDIVIDUAL PATIENT DATA META-ANALYSIS OF 2 RANDOMIZED PHASE III TRIALS.
EHA Learning Center, Francesca Gay, 215599
TREATMENT OF IGM-ASSOCIATED SYSTEMIC AL AMYLOIDOSIS WITH RITUXIMAB-BENDAMUSTINE
EHA Learning Center, Richa Manwani, 215615
AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN AL AMYLOIDOSIS: SURVIVAL IMPROVEMENT IN DIFFERENT RISK CATEGORIES IN A SINGLE CENTER EXPERIENCE

EHA Learning Center, Angelo Belotti, 215631
NLR AS SURROGATE OF MYELOID IMMUNE SUPPRESSION CAN PREDICT EARLY SPLENIC RESPONSE TO RUXOLITINIB IN MYELOFIBROSIS
EHA Learning Center, Alfio Bonanno, 215647
MIPSS70 AND TRANSFUSION DEPENDENCE PREDICT SURVIVAL IN MYELOFIBROSIS PATIENTS TREATED WITH JAK1/2 INHIBITOR THERAPY
EHA Learning Center, Caroline Mcnamara, 215663
DUAL TARGETING OF BRD4 BY AZD5153 AND BCL2 BY AZD4320 FOR HIGH-RISK B-CELL LYMPHOMAS CONCOMITANTLY OVEREXPRESSING C-MYC AND BCL2
EHA Learning Center, Junya Kuroda, 215680
RH-TPO RESTORES MEGAKARYOCYTES AND BONE MARROW NICHE COMPONENTS IN THE TREATMENT OF SEVERE THROMBOCYTOPENIA IN PATIENTS WITH CIRRHOSIS ASSOCIATED WITH HEPATITIS B
EHA Learning Center, Wan-Yi Zhai, 215697
OCCURRENCE AND MANAGEMENT OF HEPATOBILIARY ADVERSE EVENTS (AES) IN ADULTS WITH IMMUNE THROMBOCYTOPENIA (ITP) DURING LONG-TERM TREATMENT WITH ELTROMBOPAG: RESULTS FROM THE EXTEND STUDY
EHA Learning Center, Abderrahim Khelif, 215714
A HEALTH STATE UTILITY MODEL ESTIMATING THE IMPACT OF IVOSIDENIB ON QUALITY OF LIFE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
EHA Learning Center, Michael Storm, 215730
TICAGRELOR VERSUS PLACEBO FOR THE REDUCTION OF VASO-OCCLUSIVE CRISES IN PEDIATRIC SICKLE CELL DISEASE: DESIGN OF A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER PHASE 3 STUDY (HESTIA3)
EHA Learning Center, Matthew Heeney, 215747
COMBINED EVALUATION OF DISEASE RISK INDEX AND ABCG2 EXPRESSION IDENTIFY AML PATIENTS AT A VERY HIGH RISK OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
EHA Learning Center, Daniela Damiani, 215763
LIFESTYLE BEHAVIOR AMONG LYMPHOMA SURVIVORS AFTER HIGH DOSE THERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Learning Center, Hanne Bersvendsen, 215779
SERUM YKL-40 LEVELS IN PATIENTS WITH B-THALASSEMIA: RELATION TO VIRAL HEPATITIS, LIVER STIFFNESS AND HEPATIC IRON CONCENTRATION.
EHA Learning Center, Samah Mostafa, 215795
THE INFLUENCE OF PGP AND PGR PEPTIDES ON ANTICOAGULANT CAPACITY AND ANTITHROMBOTIC POTENTIAL OF BLOOD IN HEMOSTATIC DYSFUNCTION OF AGING RATS
EHA Learning Center, Tamara Obergan, 215812
AN ESSENTIAL ROLE OF LCK IN T-ALL CELL PROLIFERATION AND SURVIVAL
EHA Learning Center, Yuzhe Shi, 215892
BONE MARROW FAILURE AND PREDISPOSITION TO LEUKEMIA IN GATA2 HAPLOINSUFFICIENT MICE
EHA Learning Center, Julia Weiss, 215908
MOXETUMOMAB PASUDOTOX IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY HAIRY CELL LEUKEMIA: RESULTS OF A PIVOTAL INTERNATIONAL STUDY
EHA Learning Center, Francis Giles, 214465
ALLOGENEIC STEM CELL TRANSPLANTATION FOR PERIPHERAL T-CELL LYMPHOMAS: A STUDY OF 284 PATIENTS FROM THE SOCIÉTÉ FRANCOPHONE DE GREFFE DE MOELLE ET DE THÉRAPIE CELLULAIRE.
EHA Learning Center, Stéphanie Nguyen Quoc, 214471
RAS PATHWAY HYPERACTIVATION IS ASSOCIATED WITH INFERIOR SURVIVAL IN PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA
EHA Learning Center, Klaus Geissler, 214472
A PROSPECTIVE PHASE II STUDY OF DARATUMUMAB IN PREVIOUSLY-TREATED SYSTEMIC LIGHT- CHAIN (AL) AMYLOIDOSIS
EHA Learning Center, Arnaud Jaccard, 214545
RANDOMIZED COMPARISON OF 90 MG VERSUS 60 MG DAUNORUBICIN IN 7+3 STANDARD INDUCTION FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: RESULTS FROM THE SAL-DAUNODOUBLE TRIAL
EHA Learning Center, Christoph Röllig, 214551
RITUXIMAB INDUCES A PRO-INFLAMMATORY MICROENVIRONMENT THAT INCREASES NOTCH1 SIGNALLING IN CHRONIC LYMPHOCYTIC LEUKAEMIA CELLS.
EHA Learning Center, Jennifer Edelmann, 214555
ANALYSIS OF ANTI-THROMBOPOIETIN RECEPTOR ANTIBODYIES IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA
EHA Learning Center, Takashi Satoh, 214562
HEPCIDIN MIMETIC PTG-300 INDUCES DOSE-RELATED AND SUSTAINED REDUCTIONS IN SERUM IRON AND TRANSFERRIN SATURATION IN HEALTHY SUBJECTS
EHA Learning Center, Richard Shames, 214566
MESENCHYMAL STROMAL CELLS PROTECT ACUTE LYMPHOBLASTIC LEUKAEMIA CELLS FROM CYTARABINE INDUCED APOPTOSIS BY TRANSFER OF MITOCHONDRIA VIA TUNNELLING NANOTUBES IN A TREATMENT RESISTANT NICHE MODEL
EHA Learning Center, Richard Burt, 214611
UNEXPECTED PREVALENCES OF THE JAK2V617F AND CALR MUTATIONS IN THE GENERAL POPULATION
EHA Learning Center, Sabrina Cordua, 214616
VERY LOW DOSE PROPHYLAXIS IN CHILDREN WITH HAEMOPHILIA A: A RURAL INDIAN EXPERIENCE
EHA Learning Center, DIBYENDU DE, 215843
FINAL RESULTS OF A PHASE IB STUDY OF ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA.
EHA Learning Center, Joseph Mikhael, 214463
DECREASED INCIDENCE OF INFECTION, USE OF ANTIBACTERIALS AND DAYS IN HOSPITAL AFTER ADMINISTRATION OF CLT-008 MYELOID PROGENITOR CELLS TO SUBJECTS RECEIVING AML INDUCTION THERAPY: PHASE 2 STUDY RESULTS
EHA Learning Center, Pinkal Desai, 214467
ATRA COULD CORRECT THE IMPAIRED PROPLATELET FORMATION CAUSED BY THE TUBULIN Β1 SINGLE NUCLEOTIDE POLYMORPHISM R307H IN CORTICOSTEROID-RESISTANT ITP PATIENTS
EHA Learning Center, Chen-cong Wang, 214474
A PHASE 1, OPEN-LABEL STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ESCALATING DOSES OF LJPC-401 (SYNTHETIC HUMAN HEPCIDIN) IN PATIENTS WITH IRON OVERLOAD
EHA Learning Center, Vip Viprakasit, 214475
EFFICACY OF VENETOCLAX MONOTHERAPY IN PATIENTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA POST BTK INHIBITION THERAPY.
EHA Learning Center, Toby Eyre, 214548
IBRUTINIB DOES NOT SUPPRESS CLONAL EVOLUTION IN HIGH RISK CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Davide Rossi, 214554
PREDICTION OF LEUKEMIA FREE SURVIVAL FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION IN AML: A RISK SCORE DEVELOPED BY THE ALWP OF THE EBMT
EHA Learning Center, Roni Shouval, 214557
COMPARED ANALYSIS OF MUTATIONAL LANDSCAPE IN PEDIATRIC AND ADULT PATIENT WITH MYELODYSPLASTIC SYNDROMES
EHA Learning Center, Wenbin An, 214558
CALRETICULIN DEL52 KNOCK-IN MICE DEVELOP A DOSE-DEPENDENT THROMBOCYTOSIS AND PROGRESSION TO MYELOFIBROSIS
EHA Learning Center, Caroline Marty, 214560
GENOMIC LANDSCAPE OF ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA
EHA Learning Center, Li-Xin Wu, 214610
PHASE 1 FIRST-IN-HUMAN TRIAL OF AMV564, A BIVALENT BISPECIFIC (2×2) CD33/CD3 T-CELL ENGAGER, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
EHA Learning Center, Peter Westervelt, 214466
KD025-208: A PHASE 2 OPEN-LABEL TRIAL OF KD025-208 FOR STEROID-DEPENDENT CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD)
EHA Learning Center, Madan Jagasia, 214470
EFFECTS OF BONE MARROW MESENCHYMAL CELLS FROM IMMUNE THROMBOCYTOPENIA PATIENTS ON THE BIOLOGICAL BEHAVIORS OF MEGAKARYOCYTES
EHA Learning Center, Hua Zhong, 214473
CO-OCCURRENCE OF STAG2 AND RAS SIGNALING MUTATIONS DURING PROGRESSION FROM MDS TO SAML ANALYZED BY WHOLE-EXOME AND TARGETED-DEEP SEQUENCING
EHA Learning Center, Marta Martín Izquierdo, 214496
A HISTIDINE PATCH IN THE N-DOMAIN OF MUTANT CALRETICULIN IS REQUIRED FOR MPN PATHOGENESIS
EHA Learning Center, Jeanne Rivera, 214497
ONCE-WEEKLY VS TWICE-WEEKLY CARFILZOMIB DOSING PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS OF THE RANDOMIZED PHASE 3 STUDY A.R.R.O.W.
EHA Learning Center, Maria Victoria Mateos, 214544
PROSPECTIVE PHASE II STUDY OF VENETOCLAX (VEN) IN PATIENTS (PTS) WITH PREVIOUSLY TREATED WALDENSTROM MACROGLOBULINEMIA (WM)
EHA Learning Center, Jorge Castillo, 214547
SYK TARGETING AS A POTENTIAL THERAPEUTIC STRATEGY FOR HIGH RISK TEL-AML1 PATIENTS
EHA Learning Center, Valentina Serafin, 214553
DEVELOPMENT OF A GALNAC SIRNA CONJUGATE TARGETING TMPRSS6 FOR THE TREATMENT OF IRON OVERLOAD DISORDERS, SUCH AS B-THALASSEMIA
EHA Learning Center, Ute Schaeper, 214565
MOR202 WITH LOW-DOSE DEXAMETHASONE (DEX) OR POMALIDOMIDE/DEX OR LENALIDOMIDE/DEX IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): A PHASE I/IIA, MULTICENTER, DOSE-ESCALATION STUDY
EHA Learning Center, Marc Raab, 214462
ACALABRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA
EHA Learning Center, Roger Owen, 214464
REGULATION OF HIF-1Α IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET
EHA Learning Center, Marta Coscia, 214468
PANOBINOSTAT, DECITABINE, AND DONOR LYMPHOCYTE INFUSION POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: THE HOVON 116 STUDY IN NEWLY DIAGNOSED POOR-RISK AML PATIENTS
EHA Learning Center, Jan Cornelissen, 214550
GRAFT-VERSUS-LEUKEMIA EFFECTS IN SECONDARY ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT
EHA Learning Center, Frederic Baron, 214556
DELETION OF STAT2 INCREASES THROMBOCYTOSIS AND SURVIVAL IN A JAK2 V617F MOUSE MODEL OF MPN VIA A NON CELL-AUTONOMOUS MECHANISM.
EHA Learning Center, Gaëlle Vertenoeil, 214559
LIVER IRON CONTENT DETERMINES HEPCIDIN LEVELS
EHA Learning Center, Sandro Altamura, 214564
MODELING HIGH RISK ACUTE LEUKEMIA WITH COMBINED T-CELL AND MYELOID PHENOTYPE CAUSED BY THE ETV6-NCOA2 FUSION GENE
EHA Learning Center, Hila Fishman, 214609
EZH2 AND RUNX1 MUTATIONS COLLABORATE TO INITIATE DISTINCT HEMATOLOGICAL MALIGNANCIES DEPENDING ON THE TARGET CELL
EHA Learning Center, Christopher Booth, 214614
NLRP3 INFLAMMSOME ACTIVATION IN PBMCS CONTROLS THE T CELL RESPONSE IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA
EHA Learning Center, Mingqiang Hua, 214617
OPTIMISMM: PHASE 3 TRIAL OF POMALIDOMIDE, BORTEZOMIB, AND LOW‐DOSE DEXAMETHASONE VS BORTEZOMIB AND LOW-DOSE DEXAMETHASONE IN LENALIDOMIDE-EXPOSED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Learning Center, Paul Richardson, 214461
ADMINISTRATION OF BPX-501 CELLS FOLLOWING ALPHA/BETA T-CELL AND B-CELL-DEPLETED HLA HAPLOIDENTICAL HSCT (HAPLO-HSCT) IN CHILDREN WITH PRIMARY IMMUNODEFICIENCIES
EHA Learning Center, Daria Pagliara, 214469
MULTINATIONAL, RANDOMIZED PHASE 3 TRIAL OF IBRUTINIB-RITUXIMAB VS PLACEBO-RITUXIMAB IN PATIENTS WITH WALDENSTRÖM’S MACROGLOBULINEMIA.
EHA Learning Center, Meletios A Dimopoulos, 214546
PROSPECTIVE STUDY OF HLA-MATCHED DONOR AVAILABILITY AND SURVIVAL IN REMISSION AFTER AML IN OLDER ADULTS: 1ST PLANNED ANALYSIS FROM ECOG-ACRIN E2906 PHASE III RANDOMIZED TRIAL IN PATIENTS AGE ≥60 YEARS
EHA Learning Center, James Foran, 214549
PIGGYBAC TRANSPOSON SCREENING IDENTIFIES NOVEL CANCER GENES AND REGULATORY ELEMENTS IN T CELL LEUKEMIA
EHA Learning Center, Anja Pfaus, 214552
A STRATEGY WITH CHAPERONE-LIKE COMPOUNDS TO RESTORE EXPRESSION OF FACTOR IX VARIANTS AFFECTED BY FREQUENT MISSENSE MUTATIONS CAUSING HEMOPHILIA B
EHA Learning Center, Mirko Pinotti, 214561
INVESTIGATING THE ROLE OF NCOA4 IN ACUTE AND CHRONIC IRON RELEASE FROM STORES
EHA Learning Center, Antonella Nai, 214563
MULTIPLE MECHANISMS OF KRAS ACTIVATION IN TRISOMY 12 CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Elena Vendramini, 214612
INTRINSIC DEFECTS CAUSED BY COMBINED CSNK1A1/RPS14 AND MIRNA145/146A DEFICIENCY DIRECTLY ALTER THE MICROENVIRONMENT IN A NOVEL MOUSE MODEL FOR DEL(5Q) MDS
EHA Learning Center, Flavia Ribezzo, 214613
A NOVEL INHIBITORY MUTATION FOR JAK2 V617F TARGETING THE AROMATIC INTERACTION AROUND F617 RESTORES NORMAL FUNCTION FOR MOST OF JAK2-UTILIZING CYTOKINE RECEPTORS EXCEPT IFNGR
EHA Learning Center, Emilie Leroy, 214615
The imperative for change in adverse event reporting in hematologic malignancies
EHA Learning Center, Gita Thanarajasingam, 219187
Using patient-reported outcomes to improve toxicity assessment
EHA Learning Center, Fabio Efficace, 219188

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings